Marrone Bio Innovations, Inc. Reports Third Quarter 2018 Financial Results


Year-Over-Year Revenues Increase 29% to Third Quarter Record of $5.4 Million; Gross Margins Expand to Record 48.3%; Operating Expenses Decrease by 19% to $6.8 Million


DAVIS, Calif., November 13, 2018 -

Marrone Bio Innovations, Inc. (“MBI” or the “Company”) (NASDAQ: MBII), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, has provided its financial results for the third quarter ended September 30, 2018.


Management Commentary


“I am pleased to announce our strong third quarter financial results and continued operational execution throughout our business,” said Dr. Pam Marrone, Founder and CEO of Marrone Bio Innovations. “I am excited about what I am seeing regarding the market’s acceptance of biologicals in integrated programs with large growers. We continued to strengthen our commercial team as well through the addition of key hires, which when paired with customer education initiatives aimed at the integration of our brands into traditional programs while increasing our share in the organic market, we expect to drive continued growth as we move into 2019.


“On the financial front, we grew revenue 29% over last year to a third quarter record of $5.4 million, which is notable as the third quarter is traditionally one of our slowest times of year. In addition, our gross margins improved to a record 48.3%, while further trimming operating expenses 19% to $6.8 million. As a result of all of these factors, our cash usage from operations was the lowest in our history as a public company.


“On the technology front, we continue to be recognized throughout the industry for innovation. Venerate was recently named the Best New Biological Product at the prestigious Agrow Awards 2018, while we were awarded the renowned 2018 Bernard Blum Award for a Novel Biocontrol Solution by the International Biocontrol Manufacturers Association. When one considers our history of product introductions, as well as our recent EPA submission of our novel bioherbicide, MBI-014, and what we have in our pipeline for the near future, I believe we will continue to lead the integration of biologicals within the agricultural industry.


“We continue to see encouraging trends throughout our business, particularly in our three core areas of focus: growing revenues, increasing gross margins over the long term and diligently managing operating expenses. I believe we are well positioned to continue to execute upon our business plan, creating long-term value for our shareholders,” concluded Marrone.


Q3 2018 Financial Summary


  Revenues grew to $5.4 million in the third quarter of 2018, compared to $4.2 million in the third quarter of 2017.
  Due to the adoption of the ASC 606 accounting standard (Revenue From Contracts With Customers), 2018 over 2017 reported revenues are not strictly an apples to apples comparison.
  Gross margins in the third quarter of 2018 increased significantly to 48.3%, compared to 40.9% in the third quarter of 2017.
  Operating expenses in the third quarter of 2018 declined 19% to $6.8 million, compared to $8.3 million in the third quarter of 2017.
  Net loss in the third quarter of 2018 improved significantly to $4.4 million, compared to a net loss of $8.5 million in the third quarter of 2017.
  Cash and cash equivalents, including restricted cash, totaled $22.1 million on September 30, 2018 compared to $24.9 million on June 30, 2018, reflecting cash usage of $2.8 million in the third quarter of 2018.




Recent Operational Highlights


  Submission of MBI-014 bioherbicide to the EPA.
  Expanded MBI’s international distribution network through new deals with Hop Tri Investment Corporation in Vietnam and Cambodia and with AMC/Agrimatco in Turkey.
  Strengthened the sales team through the appointment of Barner Jones as the Director of National Sales and Account Management and Jenna Combs as the Sales Manager of the Northern California Territory.
  Awarded the 2018 Bernard Blum Award for a Novel Biocontrol Solution by the International Biocontrol Manufacturers Association in Basel, Switzerland.
  Venerate named Best New Biological Product at Agrow Awards 2018 in London, United Kingdom.
  Keith McGovern and Stuart Woolf, two major leaders in the agricultural industry, joined the Board of Directors; Formed Advisory Council to advise the Board and management’s strategic vision for the Company.
  Nominated as a finalist for the 2018 Agrow Awards in the categories of Best R&D Pipeline, Best New Biological Product and Best Industry Collaboration.
  Launched a series of grower education initiatives aimed at increasing awareness among both conventional and organic farmers and the food channel.
  Among the many positive trial data around the globe, received positive results with Grandevo and Venerate on almonds, walnuts, tomatoes, peppers and cotton in California as well as on cannabis in Canada, with Regalia in Brazil, Panama, Argentina and Tunisia, Majestene in Europe and with Stargus in California and Canada.


Conference Call and Webcast


Management will host an investor conference call today at 1:30 p.m. PST (4:30 p.m. EST) to discuss Marrone Bio Innovations’ third quarter 2018 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information:


Q3 2018 Conference Call and Webcast


Date: Tuesday, November 13, 2018

Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)

U.S. Dial-in: 1-888-254-3590

International Dial-in: 1-323-994-2093

Conference ID: 5479635



Please dial in at least 10 minutes before the start of the call to ensure timely participation.


A playback of the call will be available through December 13, 2018. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 5479635. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: MBII Q3 2018 Webcast.




About Marrone Bio Innovations


Marrone Bio Innovations, Inc. (NASDAQ: MBII) strives to lead the movement to more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies to rapidly develop seven effective and environmentally responsible pest management products to help customers operate more sustainably while uniquely improving plant health and increasing crop yields. Supported by a robust portfolio of over 400 issued and pending patents around its superior natural product chemistry, MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® Stargus® and Amplitude™, Zelto® and Zequanox®.


Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit We also use our investor relations website,, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations.


Marrone Bio Innovations Forward Looking Statements


This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the strength of the Company’s position for executing on its business plan and increasing shareholder value, and the potential benefits of the Company’s products. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.


Marrone Bio Innovations Contacts:


Pam Marrone, CEO and Founder

Jim Boyd, CFO

Telephone: +1 (530) 750-2800



Investor Relations:


Greg Falesnik

Managing Director

MZ Group – MZ North America

Main: 949-385-6449





Condensed Consolidated Balance Sheets

(In Thousands, Except Par Value)


   SEPTEMBER 30, 2018   DECEMBER 31, 2017 
   (Unaudited)   (Audited) 
Current assets:          
Cash and cash equivalents  $20,524   $786 
Restricted cash, current portion   46    487 
Accounts receivable   3,072    3,785 
Inventories, net   8,843    9,827 
Deferred cost of product revenues   1    3,063 
Prepaid expenses and other current assets   1,292    1,170 
Total current assets   33,778    19,118 
Property, plant and equipment, net   14,870    16,016 
Restricted cash, less current portion   1,560    1,560 
Other assets   333    219 
Total assets  $50,541   $36,913 
Liabilities and stockholders’ equity (deficit)          
Current liabilities:          
Accounts payable  $1,862   $3,800 
Accrued liabilities   5,933    8,189 
Accrued interest due to related parties       1,622 
Deferred revenue, current portion   356    6,193 
Derivative liability       674 
Debt, current portion   1,737    1,524 
Total current liabilities   9,888    22,002 
Deferred revenue, less current portion   2,632    2,046 
Debt, less current portion   11,882    24,407 
Debt due to related parties   7,300    37,822 
Other liabilities   794    1,287 
Total liabilities   32,496    87,564 
Commitments and contingencies (Note 10)          
Stockholders’ equity (deficit):          
Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at September 30, 2018 and December 31, 2017        
Common stock: $0.00001 par value; 250,000 shares authorized, 110,668 and 31,351 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively   1     
Additional paid in capital   293,506    214,921 
Accumulated deficit   (275,462)   (265,572)
Total stockholders’ equity (deficit)   18,045    (50,651)
Total liabilities and stockholders’ equity (deficit)  $50,541   $36,913 





Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)



   2018   2017   2018   2017 
Product  $5,310   $4,161    15,171   $14,675 
License   115    58    330    174 
Total revenues   5,425    4,219    15,501    14,849 
Cost of product revenues   2,803    2,492    8,075    8,737 
Gross profit   2,622    1,727    7,426    6,112 
Operating Expenses:                    
Research, development and patent   2,658    3,152    7,685    8,449 
Selling, general and administrative   4,117    5,174    13,861    15,590 
Total operating expenses   6,775    8,326    21,546    24,039 
Loss from operations   (4,153)   (6,599)   (14,120)   (17,927)
Other income (expense):                    
Interest expense   (300)   (804)   (1,759)   (2,308)
Interest expense, related parties       (1,098)   (451)   (3,257)
Change in fair value of financial instruments           (5,177)    
Loss on extinguishment of debt, net           (303)    
Gain on extinguishment of debt, related party           9,622     
Other income (expense), net   14    (29)   (13)   (52)
Total other income (expense), net   (286)   (1,931)   1,919    (5,617)
Net loss  $(4,439)  $(8,530)  $(12,201)  $(23,544)
Basic and diluted net loss per common share:  $(0.04)  $(0.27)  $(0.12)  $(0.83)
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:   110,568    31,351    98,067    28,507 





Condensed Consolidated Statements of Cash Flows

(In Thousands)


   2018   2017 
Cash flows from operating activities          
Net loss  $(12,201)  $(23,544)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation and amortization   1,427    1,540 
Loss (gain) on disposal of equipment       365 
Share-based compensation   1,310    1,724 
Non-cash interest expense   807    1,130 
Change in fair value of financial instruments   5,177     
Loss on extinguishment of debt, net   303     
Gain on extinguishment of debt, related party, net   (9,622)    
Net changes in operating assets and liabilities:          
Accounts receivable   713    1,723 
Inventories   984    (851)
Prepaid expenses and other assets   (359)   420 
Deferred cost of product revenues   4    (255)
Accounts payable   (1,835)   1,282 
Accrued and other liabilities   (1,794)   2,491 
Accrued interest due to related parties   (1,614)   (803)
Deferred revenue   (114)   341 
Net cash used in operating activities   (16,814)   (14,437)
Cash flows from investing activities          
Purchases of property, plant and equipment   (496)   (391)
Sale of property, plant and equipment       15 
Net cash used in investing activities   (496)   (376)
Cash flows from financing activities          
Proceeds from issuance of common stock, net of offering costs   34,485    8,188 
Proceeds from issuance of debt   2,000     
Proceeds from secured borrowings   15,402    7,831 
Reductions in secured borrowings   (15,181)   (6,631)
Repayment of debt   (190)   (340)
Repayment of capital leases       (420)
Financing costs       (215)
Net settlement of stock options   (14)    
Exercise of stock options   7    17 
Exercise of warrants   98     
Net cash provided by financing activities   36,607    8,430 
Net increase (decrease) in cash and cash equivalents and restricted cash   19,297    (6,383)
Cash and cash equivalents and restricted cash, beginning of period   2,833    12,613 
Cash and cash equivalents and restricted cash, end of period  $22,130   $6,230 
Supplemental disclosure of cash flow information          
Cash paid for interest  $2,698   $5,231 
Supplemental disclosure of non-cash investing and financing activities          
Property, plant and equipment included in accounts payable and accrued liabilities  $30   $331 
Equipment acquired with debt  $   $495 
Embedded derivative liability associated with bridge loan  $573   $ 
Conversion of debt to equity  $10,000   $ 
Conversion of bridge loan (convertible note) to equity  $6,000   $ 
Conversion of debt, related party to equity  $35,000   $ 
Conversion of accrued liabilities into equity associated with the granting of restricted stock units  $205   $ 




The following information was filed by Marrone Bio Innovations Inc (MBII) on Tuesday, November 13, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Marrone Bio Innovations Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Marrone Bio Innovations Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Log in with your credentials


Forgot your details?

Create Account